<SEC-DOCUMENT>0001437749-20-011681.txt : 20200522
<SEC-HEADER>0001437749-20-011681.hdr.sgml : 20200522
<ACCEPTANCE-DATETIME>20200522173033
ACCESSION NUMBER:		0001437749-20-011681
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200522
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200522
DATE AS OF CHANGE:		20200522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		20907213

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mlss20200522_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>mlss20200522_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 5/22/2020 9:16:25 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>U</b><b>NITED STATES </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>FORM 8-K</b>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT<br>
Pursuant to Section&nbsp;13 </b><b>o</b><b>r 15(d) of </b><b>t</b><b>he Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported): </b><b>May 22</b><b>, 20</b><b>20</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:24pt;margin:0pt;text-align:center;"><b>Milestone</b><b> </b><b>Scientific</b><b> Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b><br>
			(State or other jurisdiction<br>
			of incorporation)</p>
			</td>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>00</b><b>1</b><b>-</b><b>14053</b><br>
			(Commission<br>
			File Number)</p>
			</td>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>13-3545623</b><br>
			(IRS Employer<br>
			Identification No.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>425 Eagle Rock Avenue, Suite 403</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Roseland, NJ </b><br>
			(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>070</b><b>68</b><br>
			(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Registrant&#8217;s telephone number, including area code <b>(</b><b>973) 535-2717</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report.)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 34%; border-left: thin solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33%; border-left: thin solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: thin thin 1px; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name on exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 34%; border-left: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common Stock</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33%; border-left: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MLSS</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 34%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">NYSE American</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 30.95pt;text-align:center;">Emerging growth company &#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-right:0pt;margin-top:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>Item </b><b>8</b><b>.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><b>Other Events</b><b> </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On May 22, 2020, Milestone Scientific Inc. (the &#8220;Company&#8221;) issued a press release announcing that the Company regained compliance with the stockholder&#8217;s equity requirements under the continued listing standards of the NYSE American LLC. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(d)</b></p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Exhibits</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;">The following exhibit is filed with this report:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 54pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">99.1</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_187934.htm" style="-sec-extract:exhibit;">Press release dated May 22, 2020&nbsp;</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><i>&nbsp;</i></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="3" style="vertical-align:middle;width:39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><b>Milestone Scientific</b><b> Inc.<br>
			&nbsp;</b></p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dated: May 22, 2020&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:&nbsp;&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;border-bottom:solid 1px #000000;;width:34%;">/s/ Joseph D'Agostino</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Joseph D&#8217;Agostino&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:middle;width:100%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_187934.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_187934.htm</title>

	<!-- Generated by ThunderDome Portal - 5/22/2020 9:16:01 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><img src="ex_187934img001.jpg" style="width: 196pt; height: 70pt;"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Contact:</b><br>
David Waldman or Natalya Rudman<br>
Crescendo Communications, LLC<br>
Email: mlss@crescendo-ir.com<br>
Tel: 212-671-1020</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Milestone Scientific Regains Compliance with </b><b>New York Stock Exchange </b><b>Listing Standards</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>LIVINGSTON, NJ, </b><b>May 22, 2020</b><b> -- Milestone Scientific Inc. (</b><b>NYSE: MLSS)</b>, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today confirms that it regained compliance with the stockholder&#8217;s equity requirements under the continued listing standards of the NYSE American LLC (&#8220;Exchange&#8221;).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In November 2018, Milestone Scientific received notice from the Exchange that the Company was not then in compliance with the continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. On December 20, 2018, the Company submitted a plan to achieve compliance (the &#8220;Plan&#8221;) by May 20, 2020. The Plan was accepted by the Exchange on January 24, 2019. The Company implemented the Plan, and it received notice from the Exchange on May 20, 2020 that it is now compliant with the continued listing standards.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>About Milestone Scientific Inc.</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone&#8217;s proprietary DPS Dynamic Pressure Sensing technology&#174; is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Safe Harbor Statement</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, </i><i>201</i><i>9</i><i>. The forward</i><i>-</i><i>looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"># # #</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex_187934img001.jpg
<TEXT>
begin 644 ex_187934img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !> 08# 2(  A$! Q$!_\0
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MF+D+_$QZDGN?<T-@:=%%%2 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
